{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:47:21Z","timestamp":1789498041497,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,2,3]],"date-time":"2015-02-03T00:00:00Z","timestamp":1422921600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,2,3]],"date-time":"2015-02-03T00:00:00Z","timestamp":1422921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic Myeloid Leukemia (CML) represents a paradigm for the wider cancer field. Despite the fact that tyrosine kinase inhibitors have established targeted molecular therapy in CML, patients often face the risk of developing drug resistance, caused by mutations and\/or activation of alternative cellular pathways. To optimize drug development, one needs to systematically test all possible combinations of drug targets within the genetic network that regulates the disease. The BioModelAnalyzer (BMA) is a user-friendly computational tool that allows us to do exactly that. We used BMA to build a CML network-model composed of 54 nodes linked by 104 interactions that encapsulates experimental data collected from 160 publications. While previous studies were limited by their focus on a single pathway or cellular process, our executable model allowed us to probe dynamic interactions between multiple pathways and cellular outcomes, suggest new combinatorial therapeutic targets and highlight previously unexplored sensitivities to Interleukin-3.<\/jats:p>","DOI":"10.1038\/srep08190","type":"journal-article","created":{"date-parts":[[2015,2,3]],"date-time":"2015-02-03T10:35:40Z","timestamp":1422959740000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Drug Target Optimization in Chronic Myeloid Leukemia Using Innovative Computational Platform"],"prefix":"10.1038","volume":"5","author":[{"given":"Ryan","family":"Chuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin A.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Benque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byron","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samin","family":"Ishtiaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Piterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Vardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Koschmieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berthold","family":"Gottgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,3]]},"reference":[{"key":"BFsrep08190_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1126\/science.284.5411.79","volume":"284","author":"R Gallagher","year":"1999","unstructured":"Gallagher, R. & Appenzeller, T. Beyond reductionism. Science 284, 79\u201379, 10.1126\/science.284.5411.79 (1999).","journal-title":"Science"},{"key":"BFsrep08190_CR2","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1146\/annurev-cellbio-100109-104122","volume":"26","author":"H-Y Chuang","year":"2010","unstructured":"Chuang, H.-Y., Hofree, M. & Ideker, T. A decade of systems biology. Annu Rev Cell Dev Biol 26, 721\u2013744 (2010).","journal-title":"Annu Rev Cell Dev Biol"},{"key":"BFsrep08190_CR3","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/nbt1356","volume":"25","author":"J Fisher","year":"2007","unstructured":"Fisher, J. & Henzinger, T. A. Executable cell biology. Nat Biotechnol 25, 1239\u20131249 (2007).","journal-title":"Nat Biotechnol"},{"key":"BFsrep08190_CR4","unstructured":"Clarke, E. M., G. O. & Peled, D. Model Checking. (MIT Press., 1999)."},{"key":"BFsrep08190_CR5","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/0022-5193(69)90015-0","volume":"22","author":"SA Kauffman","year":"1969","unstructured":"Kauffman, S. A. Metabolic stability and epigenesis in randomly constructed genetic nets. J Theor Biol 22, 437\u2013467 (1969).","journal-title":"J Theor Biol"},{"key":"BFsrep08190_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s001099900023","volume":"77","author":"S Huang","year":"1999","unstructured":"Huang, S. Gene expression profiling, genetic networks and cellular states: an integrating concept for tumorigenesis and drug discovery. J Mol Med (Berl) 77, 469\u2013480 (1999).","journal-title":"J Mol Med (Berl)"},{"key":"BFsrep08190_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1006\/jtbi.2001.2335","volume":"211","author":"L Sanchez","year":"2001","unstructured":"Sanchez, L. & Thieffry, D. A logical analysis of the Drosophila gap-gene system. J Theor Biol 211, 115\u2013141 (2001).","journal-title":"J Theor Biol"},{"key":"BFsrep08190_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1752-0509-1-4","volume":"1","author":"MA Schaub","year":"2007","unstructured":"Schaub, M. A., Henzinger, T. A. & Fisher, J. Qualitative networks: a symbolic approach to analyze biological signaling networks. BMC Syst Biol 1, 4\u20134 (2007).","journal-title":"BMC Syst Biol"},{"key":"BFsrep08190_CR9","doi-asserted-by":"publisher","first-page":"900","DOI":"10.3324\/haematol.2009.015271","volume":"95","author":"T Lenaerts","year":"2010","unstructured":"Lenaerts, T., Pacheco, J. M., Traulsen, A. & Dingli, D. Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells. Haematol-Hematol J 95, 900\u2013907, 10.3324\/haematol.2009.015271 (2010).","journal-title":"Haematol-Hematol J"},{"key":"BFsrep08190_CR10","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1084\/jem.20041024","volume":"200","author":"JJ Schuringa","year":"2004","unstructured":"Schuringa, J. J., Chung, K. Y., Morrone, G. & Moore, M. A. S. Constitutive activation of STAT5A promotes human hematopoietic stem cell self-renewal and erythroid differentiation. J Exp Med 200, 623\u2013635 (2004).","journal-title":"J Exp Med"},{"key":"BFsrep08190_CR11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.mbs.2007.05.003","volume":"210","author":"S Nanda","year":"2007","unstructured":"Nanda, S., Moore, H. & Lenhart, S. Optimal control of treatment in a mathematical model of chronic myelogenous leukemia. Math Biosci 210, 143\u2013156, 10.1016\/j.mbs.2007.05.003 (2007).","journal-title":"Math Biosci"},{"key":"BFsrep08190_CR12","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MW Deininger","year":"2000","unstructured":"Deininger, M. W., Goldman, J. M. & Melo, J. V. The molecular biology of chronic myeloid leukemia. Blood 96, 3343\u20133356 (2000).","journal-title":"Blood"},{"key":"BFsrep08190_CR13","unstructured":"Cook, B., F. J., Krepska, E. & Piterman, N. in 2th International Conference on Verification, Model Checking and Abstract Interpretation Conference VMCAI'11. (ed Jhala, R. & Schmidt, D.) 134\u2013149 (Springer Verlag)."},{"key":"BFsrep08190_CR14","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1096\/fj.01-0870com","volume":"16","author":"F Liu","year":"2002","unstructured":"Liu, F. et al. Hepatocyte growth factor enhances endothelial cell barrier function and cortical cytoskeletal rearrangement: potential role of glycogen synthase kinase-3beta. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 16, 950\u2013962, 10.1096\/fj.01-0870com (2002).","journal-title":"FASEB journal: official publication of the Federation of American Societies for Experimental Biology"},{"key":"BFsrep08190_CR15","doi-asserted-by":"publisher","first-page":"8076","DOI":"10.1074\/jbc.M111501200","volume":"277","author":"J Sonoyama","year":"2002","unstructured":"Sonoyama, J. et al. Functional cooperation among Ras, STAT5 and phosphatidylinositol 3-kinase is required for full oncogenic activities of BCR\/ABL in K562 cells. J Biol Chem 277, 8076\u20138082 (2002).","journal-title":"J Biol Chem"},{"key":"BFsrep08190_CR16","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1182\/blood.V99.10.3792","volume":"99","author":"MS Holtz","year":"2002","unstructured":"Holtz, M. S. et al. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 99, 3792\u20133800 (2002).","journal-title":"Blood"},{"key":"BFsrep08190_CR17","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2005-09-3732","volume":"107","author":"M Notari","year":"2006","unstructured":"Notari, M. et al. A MAPK\/HNRPK pathway controls BCR\/ABL oncogenic potential by regulating MYC mRNA translation. Blood 107, 2507\u20132516 (2006).","journal-title":"Blood"},{"key":"BFsrep08190_CR18","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1182\/blood.V97.3.720","volume":"97","author":"TL Holyoake","year":"2001","unstructured":"Holyoake, T. L. et al. Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. Blood 97, 720\u2013728 (2001).","journal-title":"Blood"},{"key":"BFsrep08190_CR19","first-page":"1958","volume":"6","author":"C Oetzel","year":"2000","unstructured":"Oetzel, C. et al. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X. Clin Cancer Res 6, 1958\u20131968 (2000).","journal-title":"Clin Cancer Res"},{"key":"BFsrep08190_CR20","first-page":"387","volume":"3","author":"IK Hariharan","year":"1988","unstructured":"Hariharan, I. K., Adams, J. M. & Cory, S. bcr-abl oncogene renders myeloid cell line factor independent: potential autocrine mechanism in chronic myeloid leukemia. Oncogene Res 3, 387\u2013399 (1988).","journal-title":"Oncogene Res"},{"key":"BFsrep08190_CR21","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1634\/stemcells.22-4-609","volume":"22","author":"M Uchida","year":"2004","unstructured":"Uchida, M. et al. Erythropoietin overcomes imatinib-induced apoptosis and induces erythroid differentiation in TF-1\/bcr-abl cells. Stem Cells 22, 609\u2013616 (2004).","journal-title":"Stem Cells"},{"key":"BFsrep08190_CR22","doi-asserted-by":"publisher","first-page":"7977","DOI":"10.1073\/pnas.1337088100","volume":"100","author":"AA Borisy","year":"2003","unstructured":"Borisy, A. A. et al. Systematic discovery of multicomponent therapeutics. Proceedings of the National Academy of Sciences of the United States of America 100, 7977\u20137982, 10.1073\/pnas.1337088100 (2003).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"BFsrep08190_CR23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nrd2683","volume":"8","author":"J Jia","year":"2009","unstructured":"Jia, J. et al. Mechanisms of drug combinations: interaction and network perspectives. Nature reviews. Drug discovery 8, 111\u2013128, 10.1038\/nrd2683 (2009).","journal-title":"Nature reviews. Drug discovery"},{"key":"BFsrep08190_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/sj.jhh.1001312","volume":"16","author":"T Stanton","year":"2002","unstructured":"Stanton, T. & Reid, J. L. Fixed dose combination therapy in the treatment of hypertension. Journal of human hypertension 16, 75\u201378, 10.1038\/sj.jhh.1001312 (2002).","journal-title":"Journal of human hypertension"},{"key":"BFsrep08190_CR25","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nm.2309","volume":"17","author":"S Zhang","year":"2011","unstructured":"Zhang, S. et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nature medicine 17, 461\u2013469, 10.1038\/nm.2309 (2011).","journal-title":"Nature medicine"},{"key":"BFsrep08190_CR26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/00000441-200302000-00003","volume":"325","author":"SU Bokhari","year":"2003","unstructured":"Bokhari, S. U., Gopal, U. M. & Duckworth, W. C. Beneficial effects of a glyburide\/metformin combination preparation in type 2 diabetes mellitus. The American journal of the medical sciences 325, 66\u201369 (2003).","journal-title":"The American journal of the medical sciences"},{"key":"BFsrep08190_CR27","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1186\/1752-0509-4-s2-s7","volume":"4","author":"Z Wu","year":"2010","unstructured":"Wu, Z., Zhao, X. M. & Chen, L. A systems biology approach to identify effective cocktail drugs. BMC Syst Biol 4 Suppl 2S7, 10.1186\/1752-0509-4-s2-s7 (2010).","journal-title":"BMC Syst Biol"},{"key":"BFsrep08190_CR28","doi-asserted-by":"publisher","first-page":"e1002323","DOI":"10.1371\/journal.pcbi.1002323","volume":"7","author":"XM Zhao","year":"2011","unstructured":"Zhao, X. M. et al. Prediction of drug combinations by integrating molecular and pharmacological data. PLoS computational biology 7, e1002323, 10.1371\/journal.pcbi.1002323 (2011).","journal-title":"PLoS computational biology"},{"key":"BFsrep08190_CR29","doi-asserted-by":"publisher","first-page":"7325","DOI":"10.1158\/0008-5472.Can-10-0607","volume":"70","author":"JH Seo","year":"2010","unstructured":"Seo, J. H. et al. A Specific Need for CRKL in p210(BCR-ABL)-Induced Transformation of Mouse Hematopoietic Progenitors. Cancer Res 70, 7325\u20137335, 10.1158\/0008-5472.Can-10-0607 (2010).","journal-title":"Cancer Res"},{"key":"BFsrep08190_CR30","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1172\/JCI115320","volume":"88","author":"T Otsuka","year":"1991","unstructured":"Otsuka, T., Thacker, J. D., Eaves, C. J. & Hogge, D. E. Differential effects of microenvironmentally presented interleukin 3 versus soluble growth factor on primitive human hematopoietic cells. J Clin Invest 88, 417\u2013422, 10.1172\/JCI115320 (1991).","journal-title":"J Clin Invest"},{"key":"BFsrep08190_CR31","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1080\/10428190701583991","volume":"48","author":"Y Meng","year":"2007","unstructured":"Meng, Y. et al. (-)Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells. Leuk Lymphoma 48, 2204\u20132212 (2007).","journal-title":"Leuk Lymphoma"},{"key":"BFsrep08190_CR32","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.stem.2012.12.011","volume":"12","author":"DJ Goff","year":"2013","unstructured":"Goff, D. J. et al. A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell 12, 316\u2013328 (2013).","journal-title":"Cell Stem Cell"},{"key":"BFsrep08190_CR33","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1182\/blood-2012-03-380147","volume":"120","author":"R Hehlmann","year":"2012","unstructured":"Hehlmann, R. How I treat CML blast crisis. Blood 120, 737\u2013747, 10.1182\/blood-2012-03-380147 (2012).","journal-title":"Blood"},{"key":"BFsrep08190_CR34","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.drudis.2012.05.006","volume":"17","author":"S Hasan","year":"2012","unstructured":"Hasan, S., Bonde, B. K., Buchan, N. S. & Hall, M. D. Network analysis has diverse roles in drug discovery. Drug Discov Today 17, 869\u2013874, 10.1016\/j.drudis.2012.05.006 (2012).","journal-title":"Drug Discov Today"},{"key":"BFsrep08190_CR35","doi-asserted-by":"publisher","first-page":"e1002267","DOI":"10.1371\/journal.pcbi.1002267","volume":"7","author":"A Saadatpour","year":"2011","unstructured":"Saadatpour, A. et al. Dynamical and structural analysis of a T cell survival network identifies novel candidate therapeutic targets for large granular lymphocyte leukemia. PLoS computational biology 7, e1002267, 10.1371\/journal.pcbi.1002267 (2011).","journal-title":"PLoS computational biology"},{"key":"BFsrep08190_CR36","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/nature08543","volume":"462","author":"RE Moellering","year":"2009","unstructured":"Moellering, R. E. et al. Direct inhibition of the NOTCH transcription factor complex. Nature 462, 182\u2013188, 10.1038\/nature08543 (2009).","journal-title":"Nature"},{"key":"BFsrep08190_CR37","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.cell.2011.08.017","volume":"146","author":"JE Delmore","year":"2011","unstructured":"Delmore, J. E. et al. BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc. Cell 146, 903\u2013916, 10.1016\/j.cell.2011.08.017 (2011).","journal-title":"Cell"},{"key":"BFsrep08190_CR38","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/978-3-642-31424-7_50","volume":"Vol. 7358","author":"D Benque","year":"2012","unstructured":"Benque, D. et al. in Computer Aided Verification. Vol. 7358 Lecture Notes in Computer Science (eds Madhusudan, P. & SanjitA Seshia) Ch. 50, 686\u2013692 (Springer Berlin Heidelberg, 2012).","journal-title":"Lecture Notes in Computer Science"},{"key":"BFsrep08190_CR39","doi-asserted-by":"crossref","unstructured":"Taylor, A. et al. in ACM SIGCHI Conference on Human Factors in Computing Systems 493\u2013502 (ACM, Paris, France, 2013).","DOI":"10.1145\/2470654.2470725"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep08190","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep08190.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep08190.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T07:19:18Z","timestamp":1747552758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep08190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,3]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,7,15]]}},"alternative-id":["BFsrep08190"],"URL":"https:\/\/doi.org\/10.1038\/srep08190","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,3]]},"assertion":[{"value":"16 October 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8190"}}